Literature DB >> 21890088

Relation of C-reactive protein to endothelial fibrinolytic function in healthy adults.

Brian R Weil1, Jared J Greiner, Christopher A DeSouza, Brian L Stauffer.   

Abstract

Increased plasma concentrations of C-reactive protein (CRP) independently predict future atherothrombotic events in healthy asymptomatic adults. CRP may promote atherothrombosis by altering fibrinolytic balance; however, the influence of increased plasma CRP concentrations on endothelial fibrinolysis in healthy adults is unclear. We tested the hypothesis that endothelial release of tissue-type plasminogen activator (t-PA) is impaired in adults with increased plasma CRP concentrations independent of other cardiometabolic risk factors. Fifty-four healthy adults were studied: 24 with CRP <1.0 mg/L (low CRP; 18 men and 6 women, 55 ± 2 years old), 18 with CRP 1.0 to 3.0 mg/L (moderate CRP; 8 men and 10 women, 58 ± 2 years old), and 12 with CRP >3.0 mg/L (high CRP; 7 men and 5 women, 56 ± 2 years old). Net endothelial release of t-PA was determined in vivo in response to intrabrachial infusions of bradykinin (125 to 500 ng/min) and sodium nitroprusside (2.0 to 8.0 μg/min). Capacity of the endothelium to release t-PA was significantly lower (∼30%) in the high (0.32 ± 0.5 to 38.9 ± 6.0 ng · 100 ml tissue(-1) · min(-1)) and moderate (-0.05 ± 0.4 to 39.3 ± 5.2 ng · 100 ml tissue(-1) · min(-1)) compared to the low (0.42 ± 0.9 to 61.8 ± 5.2 ng · 100 ml tissue(-1) · min(-1)) CRP group. There was no significant difference in t-PA release between the high and moderate CRP groups. Plasma CRP concentrations were inversely related to t-PA release (r = -0.38, p <0.05). In conclusion, these results indicate that the capacity of the endothelium to release t-PA is decreased in adults with plasma CRP ≥1.0 mg/L. Endothelial fibrinolytic dysfunction may underlie the increased atherothrombotic risk associated with increases in plasma CRP concentrations in otherwise healthy adults.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890088      PMCID: PMC3285466          DOI: 10.1016/j.amjcard.2011.07.026

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

3.  Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion.

Authors:  F Tomai; F Crea; A Gaspardone; F Versaci; A S Ghini; L Chiariello; P A Gioffrè
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

4.  Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease.

Authors:  S J Cleland; N Sattar; J R Petrie; N G Forouhi; H L Elliott; J M Connell
Journal:  Clin Sci (Lond)       Date:  2000-05       Impact factor: 6.124

5.  Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture.

Authors:  M A Shatos; J M Doherty; D C Stump; E A Thompson; D Collen
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

6.  Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease.

Authors:  S Fichtlscherer; G Rosenberger; D H Walter; S Breuer; S Dimmeler; A M Zeiher
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

7.  Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells.

Authors:  K Kugiyama; T Sakamoto; I Misumi; S Sugiyama; M Ohgushi; H Ogawa; M Horiguchi; H Yasue
Journal:  Circ Res       Date:  1993-08       Impact factor: 17.367

8.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

9.  Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.

Authors:  Greta L Hoetzer; Brian L Stauffer; Heather M Irmiger; Marilyn Ng; Derek T Smith; Christopher A DeSouza
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

10.  Prospective study of endogenous tissue plasminogen activator and risk of stroke.

Authors:  P M Ridker; C H Hennekens; M J Stampfer; J E Manson; D E Vaughan
Journal:  Lancet       Date:  1994-04-16       Impact factor: 79.321

View more
  3 in total

1.  Elevations in C-reactive protein and endothelin-1 system activity in humans.

Authors:  Caitlin A Dow; Danielle L Templeton; Grace M Lincenberg; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  Life Sci       Date:  2015-12-11       Impact factor: 5.037

2.  Influence of dietary saturated fat intake on endothelial fibrinolytic capacity in adults.

Authors:  Caitlin A Dow; Brian L Stauffer; Jared J Greiner; Christopher A DeSouza
Journal:  Am J Cardiol       Date:  2014-06-19       Impact factor: 2.778

3.  Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model.

Authors:  Kristina Svennerholm; Niklas Bergh; Pia Larsson; Sverker Jern; Göran Johansson; Björn Biber; Michael Haney
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.